NASDAQ:AEGR - Aegerion Pharmaceuticals Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $1.97 0.00 (0.00 %) (As of 07/20/2018 12:52 PM ET)Previous Close$1.97Today's Range$1.97 - $1.9752-Week Range$1.23 - $10.85VolumeN/AAverage Volume635,262 shsMarket Capitalization$56.69 millionP/E RatioN/ADividend YieldN/ABeta0.5 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Aegerion Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the development and commercialization of therapies for patients with debilitating rare diseases. It operates through pharmaceuticals segment. Its products include lomitapide and metreleptin. Lomitapide is a small molecule microsomal triglyceride transfer protein (MTP) inhibitor. Lomitapide received marketing approval under the brand name Juxtapid (lomitapide) capsules from the United States Food and Drug Administration (FDA) as an adjunct to a low-fat diet and other lipid-lowering treatments. It also received marketing authorization for lomitapide in the European Union (EU) under the brand name LOJUXTA (lomitapide) hard capsules (LOJUXTA) as a treatment for HoFH in adults. Metreleptin is a recombinant human leptin analog that exerts its function by binding to and activating the human leptin receptor. Metreleptin is marketed in the United States under the brand name MYALEPT (metreleptin) for injection (MYALEPT). Receive AEGR News and Ratings via Email Sign-up to receive the latest news and ratings for AEGR and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry N/A Sub-IndustryBiotechnology SectorN/A SymbolNASDAQ:AEGR CUSIP00767E10 Webwww.aegerion.com Phone+1-617-5007867 Debt Debt-to-Equity Ratio-19.22 Current Ratio1.02 Quick Ratio0.67 Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book ValueN/A Price / BookN/A Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net Margins-75.07% Return on EquityN/A Return on Assets-29.21% Miscellaneous Employees318 Outstanding Shares29,540,000Market Cap$56.69 Aegerion Pharmaceuticals (NASDAQ:AEGR) Frequently Asked Questions What is Aegerion Pharmaceuticals' stock symbol? Aegerion Pharmaceuticals trades on the NASDAQ under the ticker symbol "AEGR." How were Aegerion Pharmaceuticals' earnings last quarter? Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) announced its quarterly earnings data on Monday, May, 16th. The biopharmaceutical company reported ($1.72) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.58) by $1.14. The biopharmaceutical company had revenue of $35.70 million for the quarter, compared to analyst estimates of $43 million. The business's revenue for the quarter was down 39.9% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.55) EPS. View Aegerion Pharmaceuticals' Earnings History. What is the consensus analysts' recommendation for Aegerion Pharmaceuticals? 0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aegerion Pharmaceuticals in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A." Has Aegerion Pharmaceuticals been receiving favorable news coverage? News articles about AEGR stock have trended somewhat positive on Friday, Accern Sentiment reports. The research group identifies positive and negative media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Aegerion Pharmaceuticals earned a daily sentiment score of 0.12 on Accern's scale. They also assigned media coverage about the biopharmaceutical company an impact score of 45.57 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days. How do I buy shares of Aegerion Pharmaceuticals? Shares of AEGR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Aegerion Pharmaceuticals' stock price today? One share of AEGR stock can currently be purchased for approximately $1.97. How big of a company is Aegerion Pharmaceuticals? Aegerion Pharmaceuticals has a market capitalization of $56.69 million. Aegerion Pharmaceuticals employs 318 workers across the globe. How can I contact Aegerion Pharmaceuticals? Aegerion Pharmaceuticals' mailing address is 1 Main St Ste 800, CAMBRIDGE, MA 02142-1531, United States. The biopharmaceutical company can be reached via phone at +1-617-5007867. MarketBeat Community Rating for Aegerion Pharmaceuticals (NASDAQ AEGR)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 314 (Vote Outperform)Underperform Votes: 243 (Vote Underperform)Total Votes: 557MarketBeat's community ratings are surveys of what our community members think about Aegerion Pharmaceuticals and other stocks. Vote "Outperform" if you believe AEGR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AEGR will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/20/2018 by MarketBeat.com StaffFeatured Article: What does relative strength index mean?